Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

a study on Inflammatory Bowel Disease

Summary

Eligibility
for people ages 16-80 (full criteria)
Location
at San Diego, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Keywords

Ulcerative Colitis Etrasimod APD334 Colitis Colitis, Ulcerative Ulcer Etrasimod 2 mg

Eligibility

You can join if…

Open to people ages 16-80

  1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
  2. Active UC confirmed by endoscopy

You CAN'T join if...

  1. Severe extensive colitis
  2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
  3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

Locations

  • University of California San Diego Medical Center accepting new patients
    San Diego California 92037 United States
  • San Diego Gastroenterology Medical Associates terminated
    San Diego California 92103 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Arena Pharmaceuticals
Links
Elevate UC Clinical Trial Website
ID
NCT03945188
Phase
Phase 3
Study Type
Interventional
Last Updated
Contact us about this trial